OncLive TV

Benjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.

Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.

Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.

Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.

Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.

Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.

Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.

Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.

Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.

Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.

Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.

Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.

Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.

Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.

Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.

Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.

Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.

Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.

Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.

Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.

Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.

Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.